A startup supported by FAPESP is developing a methodology that will give oncologists more precise information to help them choose the best therapeutic approach.
Researchers at a startup supported by FAPESP have developed a material that mimics conditions in the uterus and could result in a 32% rise in bovine embryo production.
BioDecision has developed a methodology that combines RNA sequencing and big data to offer the pharmaceutical industry molecular targets of interest for treatment of the disease.
The firm is supported by FAPESP and is developing an autonomous helicopter capable of spraying crops on steep hillsides.
A Brazilian startup supported by FAPESP is developing a solution to detect a biomolecule linked to the presence of migratory oral cancer cells.
A startup supported by FAPESP is developing a platform that will enable local production of enzymes to act as catalysts for chemical reactions.
Researchers supported by FAPESP have created a drug using antibodies for direct application to the skin.
A startup supported by FAPESP has developed a solution to prevent disease in fish tanks by means of environmental monitoring.
A startup supported by FAPESP is developing novel cultivars to offer growers a high-value-added option.
Developed by ImunoTera as part of a project supported by FAPESP, the molecule triggers the immune system’s response to infected cells and helps combat the disease.
The novel compound was developed in the lab but can be produced with technology already used by the industry, facilitating scale-up. It fixes phosphorus in the soil for future crop cycles and requires fewer applications. The researchers are seeking partners to mass-produce it for use in large-scale experiments.
The system created by startup Ecotrace with FAPESP’s support is designed to help poultry processors detect carcass lesions in real time.
A startup supported by FAPESP is developing a solution to detect beer spoilage microorganisms, which affect flavor and aroma, both in the brewery and at the point of sale.
The solution developed by the firm, with FAPESP’s support, is currently being validated by UN’s International Atomic Energy Agency.
The device was developed by researchers at the University of São Paulo’s Heart Institute (INCOR) and a Brazilian company with FAPESP’s support. It is biocompatible and offers other advantages over the imported product used hitherto.
